South Korea has revoked approval of Kolon Life Science's gene therapy Invossa after finding that the country falsely reported the source of an ingredient, Xinhua reported Tuesday.
Officials found that an ingredient for the osteoarthritis therapy was derived from kidney cells opposed to cartilage.
The country is additionally bringing criminal charges against Kolon for submitting a false document on the drug to regulatory authorities.
Officials noted that Invossa was approved in July 2017 after Kolon intentionally concealed possible problems with the drug.
The cell used in the treatment can potentially cause cancer.
Meanwhile, the drugmaker has denied any concealment and manipulation.
To read more NewsPoints articles, click here.